In CTCL, the involvement of TORC1 is already demonstrated by studies conducted on rapamycin, a compound that mainly inhibits this complex [31], able to reduce proliferation of CTCL cell lines, primary tumor cells [21] and tumor size in xenograft mice [22]. Here, CRTC1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.